The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Can urinary exosomes act as treatment response markers in prostate cancer?
Open accessAbstract
Background: Recently, nanometer sized vesicles (termed exosomes) have been described as a component of urine. Such vesicles may be a useful non-invasive source of markers in renal disease. Their utility as a source of markers in urological cancer remains unstudied. Our aim in this study was to investigate the feasibility and value of analysing urinary exosomes in prostate cancer patients undergoing standard therapy. Methods: Ten patients (with locally advanced PCa) provided spot urine specimens at three time points during standard therapy. Patients received 3–6 months neoadjuvant androgen deprivation therapy prior to radical radiotherapy, comprising a single phase delivering 55 Gy in 20 fractions to the prostate and 44 Gy in 20 fractions to the pelvic nodes. Patients were continued on adjuvant ADT according to clinical need. Exosomes were purified, and the phenotype compared to exosomes isolated from the prostate cancer cell line LNcaP. A control group of 10 healthy donors was included. Serum PSA was used as a surrogate treatment response marker. Exosomes present in urine were quantified, and expression of prostate markers (PSA and PSMA) and tumour-associated marker 5T4 was examined. Results: The quantity and quality of exosomes present in urine was highly variable, even though we handled all materials freshly and used methods optimized for obtaining highly pure exosomes. There was approx 2-fold decrease in urinary exosome content following 12 weeks ADT, but this was not sustained during radiotherapy. Nevertheless, PSA and PSMA were present in 20 of 24 PCa specimens, and not detected in healthy donor specimens. There was a clear treatment-related decrease in exosomal prostate markers in 1 (of 8) patient. Conclusion: Evaluating urinary-exosomes remains difficult, given the variability of exosomes in urine specimens. Nevertheless, this approach holds promise as a non-invasive source of multiple markers of malignancy that could provide clinically useful information.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546
Identification and proteomic profiling of exosomes in human urine
Pisitkun, T., Shen, R.-F., & Knepper, M. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403453101 · Cited by 2,174
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Théry, C., Masurier, C., Flament, C., Pouzieux, S., Faure, F., Tursz, T., et al. (2001) · Nature Medicine · doi:10.1038/85438 · Cited by 1,640
Malignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953
Dai, S., Wei, D., Wu, Z., Zhou, X., Wei, X., Huang, H., & Li, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.1 · Cited by 805
Production and characterization of clinical grade exosomes derived from dendritic cells
Lamparski, H. G., Metha-Damani, A., Yao, J.-Y., Patel, S., Hsu, D.-H., Ruegg, C., & Le Pecq, J.-B. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00330-7 · Cited by 700
The Regulation of Exosome Secretion: a Novel Function of the p53 Protein
Yu, X., Harris, S. L., & Levine, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4579 · Cited by 688
Zhou, H., Yuen, P. S. T., Pisitkun, T., Gonzales, P. A., Yasuda, H., Dear, J. W., Gross, P., Knepper, M. A., & Star, R. A. (2006) · Kidney International · doi:10.1038/sj.ki.5000273 · Cited by 588
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D., & Tabi, Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7249 · Cited by 574
Self-citation
Cited by
Webber, J., & Clayton, A. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.19861 · Cited by 817
Self-citationEvidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine
Fais, S., O’Driscoll, L., Borras, F. E., Buzas, E., Camussi, G., Cappello, F., Carvalho, J., Cordeiro da Silva, A., Del Portillo, H., El Andaloussi, S., et al. (2016) · ACS Nano · doi:10.1021/acsnano.5b08015 · Cited by 481
Erdbrügger, U., Blijdorp, C. J., Bijnsdorp, I. V., Borràs, F. E., Burger, D., Bussolati, B., Byrd, J. B., Clayton, A., Dear, J. W., Falcón‐Pérez, J. M., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12093 · Cited by 404
Self-citationBerrondo, C., Flax, J., Kucherov, V., Siebert, A., Osinski, T., Rosenberg, A., Fucile, C., Richheimer, S., & Beckham, C. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147236 · Cited by 266
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
Metadata
- Authors
- Mitchell, P. J., Welton, J., Staffurth, J., Court, J., Mason, M. D., Tabi, Z., & Clayton, A.
- Venue
- Journal of Translational Medicine
- Published
- 2009-01-12
- Volume
- 7
- Issue
- 1
- Pages
- 4-4
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2057155093
- Cited by
- 313
- References
- 28
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can urinary exosomes act as treatment response markers in prostate cancer? https://app.cochat.ai/papers/10.1186/1479-5876-7-4
- The paper
- Mitchell, P. J., Welton, J., Staffurth, J., Court, J., Mason, M. D., Tabi, Z., & Clayton, A. (2009). Can urinary exosomes act as treatment response markers in prostate cancer? Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-7-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
